Quantitative proteomics identifies clusterin as a novel biomarker for atherosclerosis
Our study reveals that elevated CLU expression accelerates the process of AS by activating the LRP1/AKT pathway. These data elucidate a novel pro-atherogenic role for CLU and establish the CLU/LRP1/AKT axis as a promising therapeutic target for managing AS, particularly in pathologies driven by high-fat diets.
Authors
- Dengfeng Ding (ORCID: https://orcid.org/0000-0002-7360-2200)
- X H Li
- Xinou Zheng
- Yunxiao Jia
- Yingjie Zhang
- Li Zhang
- Yuqiong Zhao
- Miaomiao Niu
- Hua Chen
- Chao Guo
- Tao Jiang
Institutions
- Beijing Union University (CN)
- Chinese PLA General Hospital (CN)
- Institute of Laboratory Animal Science (CN)
Publication Details
- Journal
- Animal Models and Experimental Medicine
- Published
- 2026-02-02
- DOI
- https://doi.org/10.1002/ame2.70143
- Primary Topic
- Clusterin in disease pathology
- Type
- article
- Field-Weighted Citation Impact
- 0.00
Funders
- National Natural Science Foundation of China